Why This Matters: Global drug pricing changes could affect when new medicines are launched in Canada — potentially leaving patients waiting longer or with fewer treatment options.
Summary: The GI Society warns that most-favoured nation (MFN) pricing in the U.S. could have significant implications for Canadians. Pharmaceutical companies may be forced to delay medicine launches in Canada or shift investment to other markets. The article calls for a more competitive and predictable policy environment that protects timely patient access to innovative medicines, while supporting investment and innovation.